Sangamo Therapeutics

Historical price data

Sangamo Therapeutics is a public biotech company focused on translating groundbreaking zinc finger technology into genomic cures for severe diseases with high unmet need. The company has built a diversified pipeline of wholly-owned and partnered programs, primarily in neurology, with key assets in late-stage clinical development for Fabry disease and hemophilia A. Sangamo's strategy combines internal development of neurology-focused therapies with strategic collaborations with major pharmaceutical companies to expand its reach and validate its platform technology.

Sangamo's core technology is its proprietary zinc finger protein platform, which enables precise DNA targeting for gene editing, gene regulation, and gene therapy applications. Its compact size allows for efficient delivery via viral vectors, particularly for challenging targets like the central nervous system.

21 drugs in pipeline

Total raised: $254M

Sangamo competes with gene therapy leaders like BioMarin in hemophilia, gene editing pioneers like CRISPR Therapeutics and Intellia, and other neurology-focused biotechs. Its differentiation is based on the versatility and compact delivery of its proprietary zinc finger platform, its focus on epigenetic repression for neurology, and its validated partnerships with multiple large pharmaceutical companies.